Select your country to display the correct information / Seleziona il tuo paese per visualizzare le informazioni corrette
Switzerland
INFOLINE  0840 888 555
logo
gravidanza
 

Transplants


Medicine makes advances every day, especially in the area of stem cells, which thanks to their unlimited possibilities for use are a focus of attention. The number of transplants is growing. Just a few months ago, a report on the first cure after a transplant of stem cells stored at birth was published.

First Cure


In 2004, a German girl with leukemia received the first transplant of stem cells taken from the umbilical cord at birth. Six years later, the doctors who performed the pioneering procedure are talking about a complete cure. The news was published in a report in the specialist journal Pediatrics.

Read the report
Download the Pediatrics report PDF

Transplants of Hematopoietic Stem Cells in Europe


(Data: European Group for Blood and Marrow Transplantation)

Since 2003, the European Group for Blood and Marrow Transplantation (EBMT) has kept a registry of hematopoietic stem cell transplants done in Europe. (Hematopoietic stem cells are found in bone marrow and cord blood). Nearly 60% of these were autologous transplants, in which the stem cells had come from the transplant patient. It should also be kept in mind that in most allogenic transplants, that is, transplants using cells that are not from the patient's own body, the stem cells come from family members - another convincing argument for private stem cell banking so that one's own cells are immediately available.

2011: 35660 transplants, 13470 allogeneic (42%) and 18605 autologous (58%)
Leukemias: 10113, 32% (94% allogeneic)
Lymphomas: 18433, 57% (12% allogeneic)
Solid tumours: 1573, 5% (5% allogeneic)
Non-malignant disorders: 1830, 6% (92% allogeneic)
Cord blood was used in 6% of total transplants

2010: 30012, 12 276 allogeneic (41%) and 17 736 autologous (59%)
30012, 12 276 allogeneic (41%) and 17 736 autologous (59%)
Leukemias: 9355 (31%; 93% allogeneic)
Lymphomas: 17 362 (58%; 12% allogeneic)
Solid tumors: 1585 (5%; 6% allogeneic)
Non-malignant disorders: 1609 (6%; 88% allogeneic)
Cord blood was used in 6% of total transplants

2009: 28033 transplants, 11494 allogeneic (41%) and 16539 autologous (59%)
Leukemias: 8691, 31% (92% allogeneic e 8% autologous)
Lymphomas: 16259, 58% (12% allogeneic e 88% autologous)
Solid tumors: 1401, 5% (6% allogeneic e 94% autologous)
Non-malignant disorders: 1682, 6% (88% allogeneic e 12% autologous)

2008: 26810 transplants, 10724 allogeneic (40%) and 16086 autologous (60%)
Leukemias: 8579, 32% (89% allogeneic e 11% autologous)
Lymphomas: 15013, 56% (11% allogeneic e 89% autologous)
Solid tumors: 1609, 6% (4% allogeneic e 96% autologous)
Non-malignant disorders: 1609, 6% (88% allogeneic e 12% autologous)

2007: 25563 transplants, 10072 allogeneic (39%) and 15491 autologous (61%)
Leukemias: 8061, 32% (89% allogeneic e 11% autologous)
Lymphomas: 14627, 57% (11% allogeneic e 89% autologous)
Solid tumors: 1488, 6% (4% allogeneic e 96% autologous)
Non-malignant disorders: 1302, 5% (91% allogeneic e 9% autologous)

2006: 25050 transplants, 9661 allogeneic (39%) and 15389 autologous (61%)
Leukemias: 7963, 32% (85% allogeneic e 15% autologous)
Lymphomas: 14169, 56% (11% allogeneic e 89% autologous)
Solid tumors: 1564, 6% (5% allogeneic e 95% autologous)
Non-malignant disorders: 1242, 5% (90% allogeneic e 10% autologous)

2005: 24168 transplants, 8890 allogeneic (37%) and 15278 autologous (63%)
Leukemias: 7404, 31% (82% allogeneic e 18% autologous)
Lymphomas: 13825, 57% (11% allogeneic e 89% autologous)
Solid tumors: 1655, 7% (8% allogeneic e 92% autologous)
Non-malignant disorders: 1131, 5% (93% allogeneic e 7% autologous)
A total of 671 planned allogeneic after autologous HSCT were reported; the majority for myeloma (52%), lymphoma (28%) and acute myeloid leukaemia (11%).

2004: 22216 transplants, 7407 allogeneic (33%) and 14809 autologous (67%)
Leukemias: 7045, 32% (78% allogeneic e 22% autologous)
Lymphomas: 12310, 55% (6% allogeneic e 94% autologous)
Solid tumors: 1759, 8% (7% allogeneic e 93% autologous)
Non-malignant disorders: 1015, 5% (di cui 93% allogeneic e 7% autologous)

2003: 21028 transplants, 7091 allogeneic (34%) and 13937 autologous(66%)
Leukemias: 6613, 31% (di cui 78% allogeneic e 22% autologous)
Lymphomas 11571, 55% (di cui 7% allogeneic e 93% autologous)
Solid tumors 1792, 9% (di cui 8% allogeneic e 92% autologous)
Non-malignant disorders 898, 5% (di cui 93% allogeneic e 7% autologous)
Page created on: 03/09/2012
Last modified on: 03/09/2012
 
 
 
Our advisors will be happy to answer
your questions with no obligation
to you.
To contact an advisor, click here
Send your data, you will be contacted as soon as possible
By clicking 'send' you authorize Genico treating your personal data